BMEA Stock Overview
A clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Biomea Fusion, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.02 |
| 52 Week High | US$22.74 |
| 52 Week Low | US$3.61 |
| Beta | -0.43 |
| 11 Month Change | -43.43% |
| 3 Month Change | -7.87% |
| 1 Year Change | -44.94% |
| 33 Year Change | -40.15% |
| 5 Year Change | n/a |
| Change since IPO | -62.26% |
Recent News & Updates
Recent updates
We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
Sep 30
We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully
Jun 10We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth
Feb 22Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?
Nov 07We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully
Jul 12Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation
Mar 29We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely
Nov 03Biomea Fusion GAAP EPS of -$0.59 beats by $0.01
Aug 01We're Not Very Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate
Jul 20Biomea Fusion (NASDAQ:BMEA) Is In A Good Position To Deliver On Growth Plans
Mar 16Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation
Nov 27Biomea Fusion: Patience Warranted
Sep 23Shareholder Returns
| BMEA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 11.8% | 4.3% | 1.6% |
| 1Y | -44.9% | 18.8% | 32.3% |
Return vs Industry: BMEA underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: BMEA underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| BMEA volatility | |
|---|---|
| BMEA Average Weekly Movement | 10.8% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BMEA's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BMEA's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 107 | Thomas Butler | biomeafusion.com |
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
Biomea Fusion, Inc. Fundamentals Summary
| BMEA fundamental statistics | |
|---|---|
| Market cap | US$249.68m |
| Earnings (TTM) | -US$144.01m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs BMEA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BMEA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$144.01m |
| Earnings | -US$144.01m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.97 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BMEA perform over the long term?
See historical performance and comparison